Amgen has moved closer to introducing in Canada its Mvasi (bevacizumab) biosimilar rival to Genentech’s Avastin, after obtaining approval from Health Canada for 100mg/4ml and 400mg/16ml single-use vials. Stating that Mvasi’s indications were granted on the “basis of similarity” between the biosimilar and Avastin, a product monograph released by Health Canada noted that Mvasi will be used to treat metastatic colorectal cancer and locally advanced, metastatic or recurrent non-small cell lung cancer.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?